TD Asset Management Inc Sells 20,085 Shares of Revvity Inc. $RVTY

TD Asset Management Inc lowered its stake in shares of Revvity Inc. (NYSE:RVTY) by 22.6% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 68,926 shares of the company’s stock after selling 20,085 shares during the quarter. TD Asset Management Inc’s holdings in Revvity were worth $6,669,000 as of its most recent SEC filing.

Other institutional investors have also bought and sold shares of the company. CYBER HORNET ETFs LLC bought a new stake in Revvity during the second quarter worth $32,000. Cromwell Holdings LLC grew its stake in Revvity by 141.4% in the 4th quarter. Cromwell Holdings LLC now owns 338 shares of the company’s stock valued at $33,000 after purchasing an additional 198 shares during the period. MUFG Securities EMEA plc bought a new position in Revvity in the 2nd quarter valued at $34,000. Headlands Technologies LLC bought a new position in Revvity in the 2nd quarter valued at $49,000. Finally, Smartleaf Asset Management LLC grew its stake in Revvity by 56.8% in the 3rd quarter. Smartleaf Asset Management LLC now owns 690 shares of the company’s stock valued at $58,000 after purchasing an additional 250 shares during the period. Institutional investors own 86.65% of the company’s stock.

Revvity Stock Up 3.8%

RVTY stock opened at $104.09 on Wednesday. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.41 and a current ratio of 1.72. The company has a market capitalization of $11.61 billion, a price-to-earnings ratio of 49.81, a PEG ratio of 2.19 and a beta of 1.11. Revvity Inc. has a fifty-two week low of $81.22 and a fifty-two week high of $118.30. The stock has a fifty day moving average of $94.07 and a 200-day moving average of $97.67.

Revvity (NYSE:RVTY) last posted its quarterly earnings results on Tuesday, May 5th. The company reported $1.06 earnings per share for the quarter, topping the consensus estimate of $1.02 by $0.04. The company had revenue of $711.12 million during the quarter, compared to the consensus estimate of $704.07 million. Revvity had a return on equity of 8.00% and a net margin of 8.26%.The firm’s quarterly revenue was up 7.0% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.01 EPS. Revvity has set its FY 2026 guidance at 5.200-5.300 EPS. As a group, equities research analysts predict that Revvity Inc. will post 5.25 earnings per share for the current year.

Revvity Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, August 7th. Stockholders of record on Friday, July 17th will be paid a dividend of $0.07 per share. The ex-dividend date is Friday, July 17th. This represents a $0.28 annualized dividend and a dividend yield of 0.3%. Revvity’s dividend payout ratio is presently 13.40%.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on RVTY. Barclays upped their price objective on Revvity from $95.00 to $105.00 and gave the company an “equal weight” rating in a research note on Thursday, May 7th. TD Cowen upped their price objective on Revvity from $115.00 to $120.00 and gave the company a “buy” rating in a research note on Wednesday, May 6th. Robert W. Baird set a $117.00 price objective on Revvity in a research note on Wednesday, May 6th. Wall Street Zen downgraded Revvity from a “buy” rating to a “hold” rating in a research note on Saturday, April 18th. Finally, Wolfe Research began coverage on Revvity in a research note on Tuesday, June 2nd. They issued a “peer perform” rating for the company. Four analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Revvity currently has an average rating of “Hold” and a consensus price target of $107.73.

Revvity Profile

Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.

Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.